• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
PTX
Click for more information
0.00% 4.7¢

PRESCIENT THERAPEUTICS LIMITED

Market Cap $37.85M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
PTX
Ann: Notification of cessation of securities - PTX 		14:34 0 235
14:34 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  235 
PTX
Ann: Change of Director's Interest Notice 		14:29 0 234
14:29 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  234 
PTX
PTX Media related
25 26 27
03/06/24 1.5K 641K
03/06/24 Last post  resort1 Comments Created with Sketch.  1.5K  Views Created with Sketch.  641K 
PTX
Ann: PTX invited to present at international lymphoma forum 		23/05/24 23 9.6K
23/05/24 Last post  Succint001 Comments Created with Sketch.  23  Views Created with Sketch.  9.6K 
PTX
Daily happenings?.
7 8 9
19/05/24 487 220K
19/05/24 Last post  VVX565 Comments Created with Sketch.  487  Views Created with Sketch.  220K 
PTX
updated chart
53 54 55
15/05/24 3.2K 1.2M
15/05/24 Last post  mrdingo Comments Created with Sketch.  3.2K  Views Created with Sketch.  1.2M 
PTX
Ann: March 2024 Quarterly Update and Appendix 4C 		10/05/24 25 10K
10/05/24 Last post  Praetorian2011 Comments Created with Sketch.  25  Views Created with Sketch.  10K 
PTX
Ann: PTX100 Ph1b results to be presented at specialist congress 		22/04/24 15 9.6K
22/04/24 Last post  Shellbell Comments Created with Sketch.  15  Views Created with Sketch.  9.6K 

See All Discussions arrow Created with Sketch.

Timeline

Notification of cessation of securities - PTX
04 Jun 14:14
 
Change of Director's Interest Notice
04 Jun 14:09
 
PTX invited to present at international lymphoma forum
20 May 09:37
 
March 2024 Quarterly Update and Appendix 4C
30 Apr 09:57
 
PTX100 Ph1b results to be presented at specialist congress
08 Apr 12:39
 
Notification of cessation of securities - PTX
05 Apr 12:55
 
View More arrow Created with Sketch.

Featured News

I88 Infini boosts WA uranium holdings with Bellah Bore East acquisition
right-arrow Created with Sketch.
NEWS Making the best of an inflationary environment
right-arrow Created with Sketch.
NEWS The Big Deal: Welcoming Warren Tredrea's words on the business of sport
right-arrow Created with Sketch.
SPA Spacetalk makes European Market Reentry with Elisa
right-arrow Created with Sketch.
PAA PharmAust reappoints MD and resets its sights on MND battle
right-arrow Created with Sketch.
TLX Telix testing shows efficacy of anti-prostate cancer therapy
right-arrow Created with Sketch.

(20min delay)
Last
4.7¢ 		Change
0.000(0.00%) 		Mkt cap ! $37.85M
Open High Low Value Volume
4.7¢ 4.7¢ 4.6¢ $13.84K 300.1K

Buyers (Bids)

No. Vol. Price($)
3 58711 4.6¢
 

Sellers (Offers)

Price($) Vol. No.
4.7¢ 184472 6
View Market Depth
Last trade - 16.10pm 04/06/2024 (20 minute delay) ?
Last
4.6¢ 		  Change
0.000 ( 2.13 %)
Open High Low Volume
4.6¢ 4.7¢ 4.6¢ 135240
Last updated 15.42pm 04/06/2024 ?
PTX (ASX) Chart

Top Stories

Wealth Within says cash is King when it comes to EML payments

Wealth Within senior analyst Filip Tortevski has been eyeing some big gun miners whose stock has been falling for a while now, contemplating the historic value of blue chips which tend to rebound spectacularly when the market improves.None of these household names, however, are Wealth Within&Clos...
ACDC discovers new heavy minerals strandline at Watchem North in Vic ACDC Metals Ltd has identified a new strandline named Venice Beach through drilling at its Watchem North project in Victoria.
Drilling doubles gold-copper mineralisation zone at GEO-01 for Antipa Antipa Minerals Ltd has announced it has doubled the mineralisation zone of its GEO-01 target in Western Australia through drilling.
Daily Market ASX Update: Waning profits suppress index | June 4, 2024 The ASX200 responded well to the latest corporate profits data from the ABS, but not enough to push the market into the green.In March, Australia’s gross corporate profits fell -2.5%, far below analyst estimates of just -0.9% for the month.This fresh evidence of a cooling economy ...
Optiscan's unveils InVue for better insights and decision-making during surgery Optiscan has unveiled InVue,  a new microscopic medical imaging device designed to enable precision surgery by putting real-time digital pathology into the hands of surgeons.

Featured News

LU7 Lithium Universe inks final layout for Becancour lithium plant as DFS rolls on
right-arrow Created with Sketch.
AVH FDA greenlights Avita's RECELL GO skin transplant cell harvesting device
right-arrow Created with Sketch.
IMM Immutep targets $100m for lung cancer drug trial tests
right-arrow Created with Sketch.
NEWS The Big Deal: Welcoming Warren Tredrea's words on the business of sport
right-arrow Created with Sketch.
PAA PharmAust reappoints MD and resets its sights on MND battle
right-arrow Created with Sketch.
HZR Hazer Group and POSCO team up to look at low carbon steel
right-arrow Created with Sketch.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.